A falling share price and an investigation involving personnel in China take center stage as AstraZeneca releases its third-quarter report. Despite these challenges, the underlying business remains robust. Strong performance across all segments has prompted the pharmaceutical giant to raise its full-year forecast.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/china-focus-as-astrazeneca-reports/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se